S5 Ep5: FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
Mar 15, 2024•23 min•Season 5Ep. 5
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
For the best experience, listen in Metacast app for iOS or Android